Amlexanox is not available in China yet or has not been generally accepted in clinical treatment. To explore the effectiveness of amlexanox oral adhesive pellicles in the treatment of minor recurrent aphthous ulcers.
ID
Bron
Verkorte titel
Aandoening
HEALTH
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Amlexanox oral adhesive pellicles significantly reduced ulcer size and alleviated ulcer pain.
Achtergrond van het onderzoek
Amlexanox has been developed as a 5% topical oral paste for the treatment of patients with RAS in most European countries. However, it is not available in China yet or has not been generally accepted in clinical treatment. To explore the effectiveness and safety of amlexanox oral adhesive pellicles in the treatment of minor recurrent aphthous ulcers, a randomized, blinded, placebo controlled, parallel, multicenter clinical study was designed. A total of 216 patients with MiRAU were recruited randomized to amlexanox or vehicle pellicles group. All patients were instructed to apply one pellicle to that identified ulcer 4 times a day (after meals and before bedtime) for 5 days (day 1 to day 5). The size and pain level of ulcers were measured and recorded on treatment days 0, 4 and 6. After five days treatment, amlexanox oral adhesive pellicles significantly reduced ulcer size and alleviated ulcer pain. None of the patients in the study was observed or reported to have any adverse experience. None of the hematologic values were considered clinically abnormal. There were also no laboratory differences between the 2 groups at baseline or day 6, and there were no significant changes over time.
Doel van het onderzoek
Amlexanox is not available in China yet or has not been generally accepted in clinical treatment. To explore the effectiveness of amlexanox oral adhesive pellicles in the treatment of minor recurrent aphthous ulcers.
Onderzoeksopzet
Five days.
Onderzoeksproduct en/of interventie
Subjects were instructed to apply 1 pellicle to that identified ulcer 4 times a day for 5 days.
Publiek
No. 14, Sec.3, Renminnan Road
Chengdu, Sichuan
Sichuan 610041
China
+86 28 85405251
qmchen@scu.edu.cn
Wetenschappelijk
No. 14, Sec.3, Renminnan Road
Chengdu, Sichuan
Sichuan 610041
China
+86 28 85405251
qmchen@scu.edu.cn
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Males and females aged 18-60 years old;
2. Willingness to participate and sign the informed consent forms;
3. Presenting with 1 to 5 aphthous ulcers (less than 72 hours duration) with a size no greater than 5 mm in diameter;
4. An expectation that their ulcers normally take 5 or more days to resolve without treatment;
5. Normal sense of pain, without anesthesia or paresthesia.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. A known history of serious drug hypersensitivities;
2. Pregnancy and lactation (Urine hCG-positive);
3. Concurrent clinical conditions that could pose a health risk to the subjects, including serious liver, kidney, and heart dysfunctions;
4. A history of an immunologic problem;
5. Ulcers as a manifestation of a systemic disease process such as ulcerative colitis, Crohns disease, Behcet¡s syndrome, or serious anemia;
6. Treatment with systemic steroid or other immunomodulatory agents within 1 month before the study entry;
7. Use of nonsteroidal anti-inflamatory drugs or oral antihistamines within 1 month prior to the study entry;
8. Treatment of the ulcer with any preparation or medication within 72 hours prior to the study entry;
9. Treatment with systemic antibiotics within 2 weeks prior to the study entry;
10. Attendance of any other clinical trials within 3 months prior to the study entry.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL1630 |
| NTR-old | NTR1727 |
| Ander register | : N/A |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |